Naturally Splendid (TSXV:NSP) announced three additional custom-formulated, flavoured hemp protein blends created by Naturally Splendid Enterprises for Laguna Blends, have received approval from Health Canada. The three additional flavours are Pro369 chocolate banana, mixed berry and vanilla caramel.
As quoted in the press release:

Pro369 is a variety of unique 30-gram single-serving (on-the-go) hemp protein powder drink mixes that are available in various flavours. The hemp proteins are water soluble and can be directly mixed in water or added to almond, coconut or regular milk. In addition, the hemp protein can also be blended into a shake or smoothie. Pro369 is considered a health industry product.


Naturally Splendid VP of Operations Bryan Carson stated:

With all four (4) custom formulated proteins now approved by Health Canada, we are moving onto the next phase with Laguna Blends. Our agreement with Laguna is not only to formulate products for them, but also to be their manufacturing partner for these products. This is a pivotal time for Naturally Splendid as we begin to monetize the technologies we have acquired. We are extremely pleased to have entered into a manufacturing agreement with Laguna Blends to be the exclusive manufacturer of their flavoured hemp Pro369 product line. We are thrilled to be involved with a company that is as committed as we are to offering products of the highest quality possible. We look forward to developing and manufacturing additional products for Laguna.

Naturally Splendid CEO Craig Goodwin said:

We are pleased that the products we’ve developed for Laguna Blends have all been approved by Health Canada. The success with these custom formulated products is a significant step forward as we attract new business opportunities. Ingredients for the custom formulated Laguna Blends products can be manufactured at the recently acquired 12,000 square foot, POS Bio Processing Centre (BPC) in Saskatoon, Saskatchewan. The POS BPC facility has the ability to produce products for the nutraceutical, medical, natural health, cosmetic and agri-food industries. Pursuant to the terms of the previously announced Purchase Agreement for POS BPC, Naturally Splendid entered into a license and sales agreement with POS Bio-Sciences, whereby Naturally Splendid will have the right to sell and market, on an exclusive basis, five (5) ingredients created using POS Bio-Sciences’ technology and to also sell and market, on a non-exclusive basis, additional ingredients created using POS technologies. The ingredients included in the licensing arrangement with POS Bio-Sciences are of high quality sourced plant and marine extracts in the form of powder or oil and will be marketed through Naturally Splendid’s recently launched BC Ingredients (BCI) division (www.bcingredients.com).

Connect with Naturally Splendid (TSXV:NSP) to receive an Investor Kit

  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less